Indication de la transfusion sanguine chez les SDM

Ferroudj, N.; Bensadok, M.; Ramaoun, Mohamed; Belhani, M; Nekkal, S.

doi:10.1016/j.tracli.2015.06.110

Cited by 2 publications

(11 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, information about the severity of hemophilia A was not available in seven studies ( n = 4,232; 93.7%). 14 15 16 18 19 20 21 Out of 4,517 patients with hemophilia A, an inhibitor was observed in 29 patients (0.6%) across four studies. 7 8 12 14 However, information about inhibitors in hemophilia were not provided in eight studies ( n = 4,029; ∼89%).…”

Section: Resultsmentioning

confidence: 99%

“…12 In addition, it was reported that two patients (<1%) had factor XIII (FXIII) deficiency, 7 13 while five patients (<1%) each were reported to have FVII deficiency and FX deficiency. 12 18 20 21 FV deficiency was reported in two patients (<1%), and congenital fibrinogen disorder and FXI deficiency were reported in one patient each (<1%). 13 20 Three studies did not differentiate between the types of RBD ( n = 13; 0.1%).…”

Section: Resultsmentioning

confidence: 99%

“…Information about the type of CBDs in hospitalized patients was not provided in five studies, 12 14 15 18 21 and in a study by Perdomo-Amar et al, information about hospitalization was not mentioned. 17 One study utilized a control group to report on the hospitalization rates of COVID-19-infected patients with CBDs.…”

Section: Resultsmentioning

confidence: 99%

“…7 8 12 14 However, information about inhibitors in hemophilia were not provided in eight studies ( n = 4,029; ∼89%). 13 15 16 17 18 19 20 21 Of the 877 patients with hemophilia B, an inhibitor was reported in seven patients (0.8%) across two studies. 8 14 The number of patients with severe, moderate, and mild hemophilia B was 28 (3.2%), 8 (∼1%), and 9 (∼1%), respectively.…”

Section: Resultsmentioning

confidence: 99%

“…7 12 In addition to our two studies, 10 other studies conducted in different parts of the world reported on approximately 700 patients with CBDs affected by COVID-19, providing us with a clearer picture of this relationship. 8 13 14 15 16 17 18 19 20 21…”

Section: Discussionmentioning

confidence: 99%

See 4 more Smart Citations

Congenital Bleeding Disorders and COVID-19—A Systematic Literature Review

Dorgalaleh,

Safdari,

Tabibian

et al. 2023

Semin Thromb Hemost

View full text Add to dashboard Cite

Hypercoagulability is a prominent feature of coronavirus disease 2019 (COVID-19) and can lead to fatal consequences. Although the impact of COVID-19 on several disorders is well-established, its effect on congenital bleeding disorders (CBDs) is not well-documented. To address this ambiguity, a systematic review was conducted on the available studies to determine the impact of COVID-19 and vaccination aimed to prevent COVID-19 on patients with CBDs. We performed a systematic literature review using relevant keywords and followed the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) protocol. We conducted our search on the PubMed, Scopus, and Web of Science databases until July 2023. Out of 31 included studies, 12 case series covering 770 patients with CBD and COVID-19 were further analyzed. The majority of the patients had hemophilia A (n = 352, ∼46%) or hemophilia B (n = 74, ∼10%), while the remaining patients had von Willebrand disease (n = 43, 5.6%) or rare bleeding disorders (n = 27, 3.5%). A total of 25 deaths (3.2%) and 22 intensive care unit admissions (2.8%) were recorded. Bleeding complications were reported in the majority of the 12 case series (n = 7, 58.3%) and in most of the case reports (n = 8, ∼57%), while thrombotic complications were only reported in two studies (16.6%). The mortality rate ranged from 0% in five studies (41.6%) to 5.7% and the rate of hospitalization ranged from 0 to 40%. Bleeding complications were reported in a range of 0 to 81%, while the thrombotic complication rate in one study was 6.9%. The mortality rate varied from 0 to 5.7%, and the hospitalization rate ranged from 0 to 40%. Bleeding complications were reported in a range of 0 to 81%, while the rate of thrombotic complications in one study was 6.9%. Vaccination was reported in five case series, which included 821 patients with CBDs with the majority having hemophilia A (n = 479; 67.2%) and hemophilia B (n = 85; ∼12%). The most frequently reported side effects were myalgia (6.5%), flu-like symptoms (4.8%), fever (4.7%), and headache (4%). COVID-19 in patients with CBDs appears to provoke thrombotic complications and bleeding events more frequently, as well as a higher rate of hospitalization, which may be partially due to the increased risk of bleeding events. Although it seems that patients with CBD have lower mortality rates, further studies are necessary to fully understand this, especially considering comorbidities and low number of available studies.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Congenital Bleeding Disorders and COVID-19—A Systematic Literature Review

Dorgalaleh,

Safdari,

Tabibian

et al. 2023

Semin Thromb Hemost

View full text Add to dashboard Cite

show abstract

Homozygous Sickle Cell Disease after Age of 40: Follow‐Up of a Cohort of 209 Patients in Senegal, West Africa

Seck,

Dabo,

Bousso

et al. 2024

Advances in Hematology

View full text Add to dashboard Cite

Objectives. The aim of this study was to describe the morbidity and mortality of homozygous sickle cell disease after the age of 40. Methods. This was a cohort study of 209 patients followed from 1994 to 2022. All hemoglobin electrophoresis-confirmed SS sickle cell patients over 40 years were included. A descriptive study of epidemiological, diagnostic, therapeutic, and evolutionary data was used to assess morbidity and mortality. Results. Sex ratio (M/F) was 0.6. Median age was 47 (41–75). According to morbidity, 95.1% had less than 3 vaso-occlusive crises/year. Acute anemia was the most frequent complication (52.63%). Chronic complications were noted in 32.5%. At diagnosis, mean hemoglobin was 8.1 g/dl ± 1.9, HbS was 86.5 ± 10, and HbF was 9.4 ± 7.6. Number of patients transfused was 66%. We noted that 8.1% of patients died, 29.2% were lost to follow-up, and 62.7% were still being followed up. The risk factors identified for death were geographical origin, comorbidity, high HbS, low HbF, and thrombocytosis. Conclusion. This study shows that homozygous SCD is increasingly becoming an adult disease and that it can be carried into old age in Africa. Advanced age over 40 is marked by an upsurge in chronic complications, making it essential to set up a screening program and to organize multidisciplinary follow-up.

show abstract

Indication de la transfusion sanguine chez les SDM

Cited by 2 publications

References 0 publications

Congenital Bleeding Disorders and COVID-19—A Systematic Literature Review

Congenital Bleeding Disorders and COVID-19—A Systematic Literature Review

Homozygous Sickle Cell Disease after Age of 40: Follow‐Up of a Cohort of 209 Patients in Senegal, West Africa

Contact Info

Product

Resources

About